Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and CEO Ted White will present at the Jefferies 2020 Healthcare Conference on June 2, 2020, from 3:30 PM to 3:55 PM ET. The presentation will focus on the company's dermatology therapeutics, particularly their late-stage candidate VP-102, aimed at treating viral skin diseases like molluscum contagiosum and common warts. The NDA for VP-102 was accepted by the FDA in November 2019, with a PDUFA goal date set for July 13, 2020. A webcast of the presentation will be available on their Investors page.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present at two virtual healthcare conferences: the Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2020, from 4:20 PM to 4:50 PM ET, and the RBC Capital Markets Global Healthcare Conference on May 19, 2020, from 4:50 PM to 5:15 PM ET. The presentations will be accessible via live webcasts on the company’s Investors page. Currently, Verrica is developing VP-102, a potential therapy for viral skin diseases, with an FDA decision slated for July 13, 2020.